The Top 60: HealthEd

HealthEd president Kristin Patton is a firm believer that what's good for the patient is good for the brand. The result is another good year for the educational marketing specialist. “It's been fantastic, and that's saying a lot considering what a challenging time it is for the healthcare industry,” says Patton. “We have experienced rapid growth and been able to partner with clients in new, more strategic ways.”

Key clients include Amylin, Eli Lilly, GlaxoSmithKline, Merck and The Leukemia and Lymphoma Society.
“We are channel-agnostic,” explains Patton, “so our primary focus is on delivering the right solution regardless of the targeted touchpoint.”

The firm took on two major initiatives in late 2007 and early 2008—the launch of sister agency HealthEd Encore and the enhancement of its interactive offering.

Patton is adamant that HealthEd's unique skill sets—it even employs certified health educators—must not become a commodity. “The industry has swung a bit from being promotional to being informational and it has changed the definition of education somewhat,” she says. “Truly effective education is grounded in the combination of behavioral science, health literacy and learning principles. It takes training, it takes certification and it yields actionable behavior.  Not every agency can do it well, but many say they can.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.